Final follicular maturation by administration of GnRH agonist plus HCG versus HCG in normal responders in ART cycles: An RCT

Maryam Eftekhar, Maryam Farid Mojtahedi, Sepideh Miraj, Malihe Omid, Maryam Eftekhar, Maryam Farid Mojtahedi, Sepideh Miraj, Malihe Omid

Abstract

Background: Gonadotropin-releasing hormone agonists (GnRH-a) was increasingly used for triggering oocyte maturationfor the prevention of ovarian hyperstimulation syndrome. Studies suggest that GnRH-a might be used as a better trigger agent since it causes both Luteinizing hormone and follicle stimulating hormone release from a physiologic natural cycle.

Objective: The aim of this study was to evaluate the effect of dual-triggering in assisted reproductive technology outcomes.

Materials and methods: 192 normal responder women aged ≤42 years and 18< Body Mass Index <30 kg/m2 enrolled in this single-blind randomized controlled trial. All participants received antagonist protocol. For final triggering, women randomly were divided into two groups. Group, I was triggered by 6500 IU human chorionic gonadotropin (hCG) alone, and group II by 6500 IU hCG plus 0.2 mg of triptorelin. The implantation, chemical, clinical and ongoing pregnancy, and abortion rates were measured.

Results: The mean of retrieved oocytes and obtained embryos were statistically higher in the dual-trigger group (group I), but the implantation and pregnancy rates were similar in two groups.

Conclusion: The results of our study did not confirm the favorable effect of dual-triggered oocyte maturation with a GnRH-a and a standard dosage of hCG as an effective strategy to optimize pregnancy outcome for normal responders in GnRH-antagonist cycles. We think that this new concept requires more studies before becoming a universal controlled ovarian hyperstimulation protocol in in vitro fertilization practice.

Keywords: Agonist; Antagonist; Gonadotropin-releasing hormone; Human chorionic gonadotropin; Normal responder; Trigger.

Conflict of interest statement

The authors report no declarations of interest.

Figures

Figure 1
Figure 1
Flowchart of the study design

References

    1. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87:709–715.
    1. Eftekhar M, MirajS , MortazavifarZ The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS. Int J Reprod BioMed. 2016;14:507.
    1. Gonen Y, Balakier H, Powell W, Casper RF. Use of Gonadotropin-Releasing Hormone Agonist to Trigger Follicular Maturation for in Vitro Fertilization. J Clin Endocrinol Metab. 1990;71:918–922.
    1. Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, et al. LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signaling. PLoS One. 2012;7:e46682.
    1. Haas J, Ophir L, Barzilay E, Yerushalmi GM, Yung Y, Kedem A, et al. GnRH agonist vs hCG for triggering of ovulation-differential effects on gene expression in human granulosa cells. PloS One . 2014;9:e90359.
    1. Haas J, Zilberberg E, Dar Sh, Kedem A, Machtinger R, Orvieto R, et al. Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles-a preliminary report. J Ovarian Res. 2014;7:77.
    1. Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013;100:1296–1302.
    1. Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, et al. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2008;90:1087–1093.
    1. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril. 2011;95:2715–2717.
    1. Rosini R, Campisi E, De Chiara M, Tettelin H, Rinaudo D, Toniolo C, et al. Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population. PLoS One . 2015;10:e0125985.
    1. Kilpi TM, Silfverdal SA, Nilsson L, Syrjänen R, Belloni C, Desole M, et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin. 2009;5:18–25.
    1. Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertil Steril. 2014;102:405–409.
    1. Decleer W, OsmanagaogluK , SeynhaveB , KolibianakisS , TarlatzisB , DevroeyP Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial. Facts Views Vis Obstet Gynecol. 2014;6:203–209.
    1. Casañ EM, Raga F, Bonilla-Musoles F, Polan ML. Human Oviductal Gonadotropin-Releasing Hormone: Possible Implications in Fertilization, Early Embryonic Development, and Implantation 1. J Clin Endocrinol Metab. 2000;85:1377–1381.
    1. Eftekhar M, Dehghani Firouzabadi R, Karimi H, Rahmani E. Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol. Iran J Reprod Med. 2012;10:297–302.
    1. Kol S. Embryo implantation and GnRH antagonists GnRH antagonists in ART: lower embryo implantation? Hum Reprod. 2000;15:1881–1882.
    1. Liu J, Cao B, Li YX, Wu XQ, Wang YL. GnRH I and II up-regulate MMP-26 expression through the JNK pathway in human cytotrophoblasts. Reprod Biol Endocrinol. 2010;8:1.
    1. Sasaki K, Norwitz ER. Gonadotropin-releasing hormone/gonadotropin-releasing hormone receptor signaling in the placenta. Curr Opin Endocrinol Diabetes Obes. 2011;18:401–408.
    1. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertil Steril. 2008;89:1234–1239.
    1. Orvieto R. Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom? J Assist Reprod Genet. 2016;33:1415–1416.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe